Table 2. Adverse events.
| Adverse events | Docetaxel + bevacizumab (N=51), n (%) | Pemetrexed + bevacizumab (N=52), n (%) | |||
|---|---|---|---|---|---|
| Any grade | ≥Grade 3 | Any grade | ≥Grade 3 | ||
| Leukopenia | 46 (90.2)* | 35 (68.6)* | 40 (76.9) | 14 (26.9) | |
| Neutropenia | 47 (92.3)* | 44 (86.3)* | 37 (71.2) | 23 (44.2) | |
| Anemia | 47 (92.3)* | 1 (2.0) | 43 (82.7) | 3 (5.8) | |
| Thrombocytopenia | 15 (29.4) | 0 | 35 (67.3)* | 2 (3.8) | |
| Febrile neutropenia | 8 (15.7) | 8 (15.7) | 6 (11.5) | 6 (11.5) | |
| INR increased | 3 (5.9) | 0 | 8 (15.4) | 0 | |
| Hypoalbuminemia | 49 (96.1) | 0 | 46 (88.5) | 0 | |
| Blood bilirubin increased | 7 (13.7) | 0 | 10 (19.2) | 0 | |
| AST increased | 10 (19.6) | 0 | 38 (73.1) | 2 (3.8) | |
| ALT increased | 5 (9.8) | 0 | 31 (59.6) | 2 (3.8) | |
| ALP increased | 14 (27.5) | 1 (2.0) | 17 (32.7) | 1 (1.9) | |
| Creatinine increased | 5 (9.8) | 0 | 14 (26.9) | 0 | |
| Hyponatremia | 20 (39.2) | 2 (3.9) | 12 (23.1) | 3 (5.8) | |
| Hyperkalemia | 14 (27.5) | 1 (2.0) | 12 (23.1) | 1 (1.9) | |
| Hypokalemia | 3 (5.9) | 0 | 9 (17.3) | 0 | |
| Anorexia | 10 (19.6) | 1 (2.0) | 14 (26.9) | 1 (1.9) | |
| Mucositis oral | 6 (11.8) | 2 (3.9) | 6 (11.5) | 0 | |
| Dysgeusia | 7 (13.7) | 0 | 4 (7.7) | 0 | |
| Nausea | 17 (33.3) | 1 (2.0) | 20 (38.5) | 0 | |
| Vomiting | 4 (7.8) | 0 | 8 (15.4) | 0 | |
| Diarrhea | 10 (19.6) | 1 (2.0) | 9 (17.3) | 0 | |
| Constipation | 7 (13.7) | 0 | 15 (28.8) | 0 | |
| Alopecia | 25 (49.0) | 0 | 0 | 0 | |
| Weight loss | 15 (29.4) | 1 (2.0) | 15 (28.8) | 1 (1.9) | |
| Fatigue | 23 (45.1) | 5 (9.8)* | 18 (34.6) | 0 | |
| Fever | 4 (7.8) | 0 | 8 (15.4) | 0 | |
| Hypertension | 34 (66.7) | 6 (11.8) | 35 (67.3) | 10 (19.2) | |
| Proteinuria | 23 (45.1) | 2 (3.9) | 29 (55.8) | 3 (5.8) | |
| Edema limbs | 4 (7.8) | 0 | 7 (13.5) | 0 | |
| Epistaxis | 14 (27.5) | 0 | 16 (30.8) | 1 (1.9) | |
Note: Listed are adverse events which were occurred in ≥10% of patients in either group. Data are presented as No. (%). Adverse events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Event (NCI-CTCAE), ver. 4.03. Asterisk (*) means that there is a statistical difference (P<0.05). INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.